Trials / Completed
CompletedNCT01804842
Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM
A Randomized, Crossover Study Assessing the Effect of EFB0027 on Plasma Glucose and Pharmacokinetics in Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Elcelyx Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study compared the effects of delayed-release metformin (Met DR, EFB0027) administered once daily in the morning (qAM), administered once daily in the evening (qPM), and administered twice daily (BID) on circulating glucose concentrations and metformin pharmacokinetics (PK) in subjects with type 2 diabetes mellitus (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Met DR | metformin delayed-release tablets |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2013-03-05
- Last updated
- 2016-10-21
- Results posted
- 2016-04-07
Source: ClinicalTrials.gov record NCT01804842. Inclusion in this directory is not an endorsement.